<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463915</url>
  </required_header>
  <id_info>
    <org_study_id>18.0209</org_study_id>
    <nct_id>NCT03463915</nct_id>
  </id_info>
  <brief_title>Clinical Trial Comparing Two Bladder Instillations for IC/BPS</brief_title>
  <official_title>Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olivia Cardenas-Trowers, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interstitial cystitis/bladder pain syndrome (IC/BPS) is a condition that results in long-term&#xD;
      bladder and pelvic pain. IC/BPS affects women more often than men. How the disorder develops&#xD;
      is not completely known. Bladder instillation is a commonly used treatment in which a mixture&#xD;
      of different ingredients are passed into the bladder to help IC/BPS symptoms. There is room&#xD;
      to learn more about bladder instillations and which ingredients in them work best. The&#xD;
      purpose of this study is to compare the effectiveness of a bladder instillation that contains&#xD;
      a steroid (triamcinolone acetonide) to a bladder instillation that does not contain a steroid&#xD;
      to treat IC/BPS in women. The study hypothesis is that women with IC/BPS treated with bladder&#xD;
      instillations that contain a steroid will have improved outcomes compared to women treated&#xD;
      with bladder instillations that do not contain a steroid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic pain disorder involving the&#xD;
      genitourinary tract. IC/BPS disproportionately affects women with over 80% of patients with&#xD;
      IC/BPS as female. Like other chronic pain conditions, IC/BPS is physically and emotionally&#xD;
      taxing on patients. IC/BPS costs the United States over $100 million annually due to direct&#xD;
      healthcare costs and loss of worker productivity. The exact pathophysiology of the disease is&#xD;
      unknown, leading to a limitation in our ability to treat the disorder effectively. The&#xD;
      current leading etiologic theory is that IC/BPS is a neurologically-derived chronic systemic&#xD;
      pain syndrome due to its association with musculoskeletal pelvic pain, irritable bowel&#xD;
      syndrome, chronic fatigue syndrome, fibromyalgia, and vulvodynia. Although several options&#xD;
      exist to treat IC/BPS, therapeutic effects are often transient. Previous studies in chronic&#xD;
      pain disorders have shown that multimodal treatment is more effective than single-agent&#xD;
      treatment, so future therapy should aim to augment rather than replace current treatments.&#xD;
      Bladder instillation is a commonly used treatment in which a mixture of different agents is&#xD;
      instilled into the bladder to improve IC/BPS symptoms. The data on the efficacy of bladder&#xD;
      instillations, as well as which ingredients in the mixture are effective, are limited. Small&#xD;
      studies have shown the potential of steroids in decreasing IC/BPS; the mechanism of action is&#xD;
      hypothesized to be due to decrease inflammation in the bladders of these patients. The&#xD;
      knowledge gap that exists is the necessity of a steroid in the bladder instillation treatment&#xD;
      for IC/BPS symptoms especially since this tends to be the most expensive ingredient.&#xD;
&#xD;
      To evaluate the utility of a steroid in the bladder instillation treatment of IC/BPS, we&#xD;
      propose a randomized, double-blind, controlled trial that will compare the efficacy of&#xD;
      bladder instillations with and without triamcinolone acetonide on IC/BPS symptoms in women.&#xD;
      We hypothesize that the addition of triamcinolone acetonide in bladder instillation therapy&#xD;
      will result in a more robust treatment response than bladder instillations without&#xD;
      triamcinolone acetonide. Our rationale is based on 1) the results of small studies that&#xD;
      showed improvement of IC/BPS symptoms with use of a steroid and 2) the hypothesized mechanism&#xD;
      of action of steroids decreasing inflammation in the bladder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Actual">October 23, 2020</completion_date>
  <primary_completion_date type="Actual">October 23, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire</measure>
    <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
    <description>Total scores range: 0-36 (0= no symptoms to 36= the most severe symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pelvic Pain and Urgency/Frequency (PUF) Questionnaire</measure>
    <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
    <description>Total scores range: 0-35 (0= no symptoms to 35= the most severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overactive Bladder Questionnaire (OAB-q)</measure>
    <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
    <description>Total scores range: 0-100 (higher scores on the symptom-severity scale suggestive of greater severity of symptoms and higher scores on the quality-of-life scale suggestive of better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Distress Inventory (PFDI)</measure>
    <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
    <description>20 question self-administered questionnaire on the presence and absence of pelvic floor symptoms. Score ranges from 0 (least distress) to 300 (most distress).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Function Measured by the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR) Questionnaire</measure>
    <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
    <description>Measures sexual function in women with pelvic floor disorders. Queries about arousal, orgasm, partner-related issues, sexual quality, and desire. The tool also takes into account those who are not sexually active. The questionnaire was used in the study solely to determine if patients had improved dyspareunia (as a categorical variable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Treatment Response as Measured by the Visual Analogue Scale (VAS) for Pain</measure>
    <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
    <description>VAS is measured on marking on a 10-centimeter (cm) ruler (measured in cm, 0= no pain and 10= most severe pain possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Adverse Event</measure>
    <time_frame>End of study (6 weeks)</time_frame>
    <description>Adverse events will only be those determined to be related to the study drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Interstitial Cystitis</condition>
  <condition>Bladder Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Bladder instillation WITH triamcinolone acetonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six weekly bladder instillations of standard cocktail plus triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bladder instillation WITHOUT triamcinolone acetonide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Six weekly bladder instillations of standard cocktail without triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bladder instillation WITH triamcinolone acetonide</intervention_name>
    <description>Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).</description>
    <arm_group_label>Bladder instillation WITH triamcinolone acetonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bladder instillation WITHOUT triamcinolone acetonide</intervention_name>
    <description>Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
    <arm_group_label>Bladder instillation WITHOUT triamcinolone acetonide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 18 years and older&#xD;
&#xD;
          -  Women with IC/BPS who have a score of ≥ 6 on either index (problem or symptom index)&#xD;
             of the O'Leary-Sant questionnaire who have selected bladder instillations as part of&#xD;
             their IC/BPS treatment&#xD;
&#xD;
          -  Suitability for follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications and/or allergies to the ingredients used in the bladder&#xD;
             instillations&#xD;
&#xD;
          -  Diagnosis of idiopathic thrombocytopenic purpura&#xD;
&#xD;
          -  Does not desire to undergo bladder instillation therapy or unwilling to undergo&#xD;
             bladder instillation therapy on schedule mandated by study&#xD;
&#xD;
          -  Have a known alternative diagnosis explaining bladder pain symptoms that would&#xD;
             preclude the diagnosis of IC/BPS (e.g. radiation cystitis, active urinary tract&#xD;
             infection with bacteria or fungus treated within last 2 weeks or diagnosed at index&#xD;
             visit, bladder injury or trauma within the last 30 days)&#xD;
&#xD;
          -  Inability to speak or read English&#xD;
&#xD;
          -  Bladder instillation within the past 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivia Cardenas-Trowers, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sean Francis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville Urogynecology at Springs Medical Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Clemens JQ, Meenan RT, Rosetti MC, Gao SY, Calhoun EA. Prevalence and incidence of interstitial cystitis in a managed care population. J Urol. 2005 Jan;173(1):98-102; discussion 102.</citation>
    <PMID>15592041</PMID>
  </reference>
  <reference>
    <citation>Nickel JC. Interstitial cystitis: a chronic pelvic pain syndrome. Med Clin North Am. 2004 Mar;88(2):467-81, xii. Review.</citation>
    <PMID>15049588</PMID>
  </reference>
  <reference>
    <citation>Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med. 2001 May 1;134(9 Pt 2):868-81. Review.</citation>
    <PMID>11346323</PMID>
  </reference>
  <reference>
    <citation>Alagiri M, Chottiner S, Ratner V, Slade D, Hanno PM. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology. 1997 May;49(5A Suppl):52-7.</citation>
    <PMID>9146002</PMID>
  </reference>
  <reference>
    <citation>Bullones Rodríguez MÁ, Afari N, Buchwald DS; National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Urological Chronic Pelvic Pain. Evidence for overlap between urological and nonurological unexplained clinical conditions. J Urol. 2013 Jan;189(1 Suppl):S66-74. doi: 10.1016/j.juro.2012.11.019. Review.</citation>
    <PMID>23234637</PMID>
  </reference>
  <reference>
    <citation>Clauw DJ, Schmidt M, Radulovic D, Singer A, Katz P, Bresette J. The relationship between fibromyalgia and interstitial cystitis. J Psychiatr Res. 1997 Jan-Feb;31(1):125-31.</citation>
    <PMID>9201654</PMID>
  </reference>
  <reference>
    <citation>Dawson TE, Jamison J. Intravesical treatments for painful bladder syndrome/ interstitial cystitis. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD006113. Review.</citation>
    <PMID>17943887</PMID>
  </reference>
  <reference>
    <citation>Pazin C, de Souza Mitidieri AM, Silva AP, Gurian MB, Poli-Neto OB, Rosa-E-Silva JC. Treatment of bladder pain syndrome and interstitial cystitis: a systematic review. Int Urogynecol J. 2016 May;27(5):697-708. doi: 10.1007/s00192-015-2815-5. Epub 2015 Aug 14. Review.</citation>
    <PMID>26272202</PMID>
  </reference>
  <reference>
    <citation>Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008943. doi: 10.1002/14651858.CD008943.pub2. Review.</citation>
    <PMID>22786518</PMID>
  </reference>
  <reference>
    <citation>Cvach K, Rosamilia A. Review of intravesical therapies for bladder pain syndrome/interstitial cystitis. Transl Androl Urol. 2015 Dec;4(6):629-37. doi: 10.3978/j.issn.2223-4683.2015.10.07. Review.</citation>
    <PMID>26816864</PMID>
  </reference>
  <reference>
    <citation>Barua JM, Arance I, Angulo JC, Riedl CR. A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2016 Aug;27(8):1137-47. doi: 10.1007/s00192-015-2890-7. Epub 2015 Nov 20. Review.</citation>
    <PMID>26590137</PMID>
  </reference>
  <reference>
    <citation>Soucy F, Grégoire M. Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. J Urol. 2005 Mar;173(3):841-3; discussion 843.</citation>
    <PMID>15711286</PMID>
  </reference>
  <reference>
    <citation>Cox M, Klutke JJ, Klutke CG. Assessment of patient outcomes following submucosal injection of triamcinolone for treatment of Hunner's ulcer subtype interstitial cystitis. Can J Urol. 2009 Apr;16(2):4536-40.</citation>
    <PMID>19364425</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <results_first_submitted>June 25, 2021</results_first_submitted>
  <results_first_submitted_qc>August 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2021</results_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Olivia Cardenas-Trowers, M.D.</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Interstitial cystitis</keyword>
  <keyword>Bladder pain syndrome</keyword>
  <keyword>IC/BPS</keyword>
  <keyword>Women</keyword>
  <keyword>Pelvic pain</keyword>
  <keyword>Urologic pain</keyword>
  <keyword>Bladder instillation</keyword>
  <keyword>Kenalog</keyword>
  <keyword>Steroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified raw data and other supporting materials will be made available to approved investigators. Email requests to olivia.cardenas-trowers@louisville.edu.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available beginning 1 month and ending 24 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>Available to investigators whose proposed use of the data is for individual participant data meta-analysis and has been approved by an independent review committee for this purpose. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03463915/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were women with IC/BPS who were recruited from January 2019 to October 2020 from the University of Louisville Female Pelvic Medicine &amp; Reconstructive Surgery clinic in Louisville, KY.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bladder Instillation WITH Triamcinolone Acetonide</title>
          <description>Six weekly bladder instillations WITH triamcinolone acetonide: mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 mg)/1 mL.</description>
        </group>
        <group group_id="P2">
          <title>Bladder Instillation WITHOUT Triamcinolone Acetonide</title>
          <description>Six weekly bladder instillations WITHOUT triamcinolone acetonide: mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bladder Instillation WITH Triamcinolone Acetonide</title>
          <description>Six weekly bladder instillations WITH triamcinolone acetonide: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 mg/1 mL).</description>
        </group>
        <group group_id="B2">
          <title>Bladder Instillation WITHOUT Triamcinolone Acetonide</title>
          <description>Six weekly bladder instillations WITHOUT triamcinolone acetonide: mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="13.3"/>
                    <measurement group_id="B2" value="46.6" spread="14.0"/>
                    <measurement group_id="B3" value="42.0" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire</title>
        <description>Total scores range: 0-36 (0= no symptoms to 36= the most severe symptoms)</description>
        <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bladder Instillation WITH Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations of standard cocktail plus triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).&#xD;
Bladder instillation WITH triamcinolone acetonide: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).</description>
          </group>
          <group group_id="O2">
            <title>Bladder Instillation WITHOUT Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations of standard cocktail without triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).&#xD;
Bladder instillation WITHOUT triamcinolone acetonide: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire</title>
          <description>Total scores range: 0-36 (0= no symptoms to 36= the most severe symptoms)</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="7.1"/>
                    <measurement group_id="O2" value="-5.8" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pelvic Pain and Urgency/Frequency (PUF) Questionnaire</title>
        <description>Total scores range: 0-35 (0= no symptoms to 35= the most severe symptoms)</description>
        <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bladder Instillation WITH Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITH triamcinolone acetonide: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 mg/1 mL).</description>
          </group>
          <group group_id="O2">
            <title>Bladder Instillation WITHOUT Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITHOUT triamcinolone acetonide: mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Pelvic Pain and Urgency/Frequency (PUF) Questionnaire</title>
          <description>Total scores range: 0-35 (0= no symptoms to 35= the most severe symptoms)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="5.1"/>
                    <measurement group_id="O2" value="-2.7" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overactive Bladder Questionnaire (OAB-q)</title>
        <description>Total scores range: 0-100 (higher scores on the symptom-severity scale suggestive of greater severity of symptoms and higher scores on the quality-of-life scale suggestive of better quality of life)</description>
        <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bladder Instillation WITH Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITH triamcinolone acetonide: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 mg/1 mL).</description>
          </group>
          <group group_id="O2">
            <title>Bladder Instillation WITHOUT Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITHOUT triamcinolone acetonide: mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Overactive Bladder Questionnaire (OAB-q)</title>
          <description>Total scores range: 0-100 (higher scores on the symptom-severity scale suggestive of greater severity of symptoms and higher scores on the quality-of-life scale suggestive of better quality of life)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.2" spread="19.1"/>
                    <measurement group_id="O2" value="-18.8" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pelvic Floor Distress Inventory (PFDI)</title>
        <description>20 question self-administered questionnaire on the presence and absence of pelvic floor symptoms. Score ranges from 0 (least distress) to 300 (most distress).</description>
        <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bladder Instillation WITH Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITH triamcinolone acetonide: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 mg/1 mL).</description>
          </group>
          <group group_id="O2">
            <title>Bladder Instillation WITHOUT Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITHOUT triamcinolone acetonide: mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Pelvic Floor Distress Inventory (PFDI)</title>
          <description>20 question self-administered questionnaire on the presence and absence of pelvic floor symptoms. Score ranges from 0 (least distress) to 300 (most distress).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="9.5"/>
                    <measurement group_id="O2" value="-6.4" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Function Measured by the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR) Questionnaire</title>
        <description>Measures sexual function in women with pelvic floor disorders. Queries about arousal, orgasm, partner-related issues, sexual quality, and desire. The tool also takes into account those who are not sexually active. The questionnaire was used in the study solely to determine if patients had improved dyspareunia (as a categorical variable).</description>
        <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bladder Instillation WITH Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITH triamcinolone acetonide: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 mg/1 mL).</description>
          </group>
          <group group_id="O2">
            <title>Bladder Instillation WITHOUT Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITHOUT triamcinolone acetonide: mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Function Measured by the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR) Questionnaire</title>
          <description>Measures sexual function in women with pelvic floor disorders. Queries about arousal, orgasm, partner-related issues, sexual quality, and desire. The tool also takes into account those who are not sexually active. The questionnaire was used in the study solely to determine if patients had improved dyspareunia (as a categorical variable).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Treatment Response as Measured by the Visual Analogue Scale (VAS) for Pain</title>
        <description>VAS is measured on marking on a 10-centimeter (cm) ruler (measured in cm, 0= no pain and 10= most severe pain possible)</description>
        <time_frame>Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bladder Instillation WITH Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITH triamcinolone acetonide: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 mg/1 mL).</description>
          </group>
          <group group_id="O2">
            <title>Bladder Instillation WITHOUT Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITHOUT triamcinolone acetonide: mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Treatment Response as Measured by the Visual Analogue Scale (VAS) for Pain</title>
          <description>VAS is measured on marking on a 10-centimeter (cm) ruler (measured in cm, 0= no pain and 10= most severe pain possible)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="2.6"/>
                    <measurement group_id="O2" value="-1.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Adverse Event</title>
        <description>Adverse events will only be those determined to be related to the study drug</description>
        <time_frame>End of study (6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bladder Instillation WITH Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITH triamcinolone acetonide: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 mg/1 mL).</description>
          </group>
          <group group_id="O2">
            <title>Bladder Instillation WITHOUT Triamcinolone Acetonide</title>
            <description>Six weekly bladder instillations WITHOUT triamcinolone acetonide: mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Adverse Event</title>
          <description>Adverse events will only be those determined to be related to the study drug</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 6 weeks.</time_frame>
      <desc>The risk for these severe events is low because the risk of the intervention is known to be low.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bladder Instillation WITH Triamcinolone Acetonide</title>
          <description>Six weekly bladder instillations of standard cocktail plus triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).&#xD;
Bladder instillation WITH triamcinolone acetonide: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).</description>
        </group>
        <group group_id="E2">
          <title>Bladder Instillation WITHOUT Triamcinolone Acetonide</title>
          <description>Six weekly bladder instillations of standard cocktail without triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).&#xD;
Bladder instillation WITHOUT triamcinolone acetonide: Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Strong bladder spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sean Francis</name_or_title>
      <organization>University of Louisville</organization>
      <phone>502-561-7260</phone>
      <email>Sean.francis@louisville.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

